Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph early_phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

completed267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Transgender Estradiol Affirming Therapy

NCT05010707
terminatedearly_phase_1

Coagulation and Fibrinolysis of Estradiol in Transwomen

NCT05387577
completedphase_3

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

NCT02616068

Clinical Trials (3)

Showing 3 of 3 trials
NCT05010707Phase 2

Transgender Estradiol Affirming Therapy

Completed
NCT05387577Early Phase 1

Coagulation and Fibrinolysis of Estradiol in Transwomen

Terminated
NCT02616068Phase 3

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3